Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a Form 8.3, disclosing its interest in Avadel Pharmaceuticals plc. The data, dated January 12, 2026, reveals that Vanguard holds 5,871,536 ordinary shares, representing 6.03% of the company's share capital.

This disclosure is made under the guidelines of the Irish Takeover Panel Act and pertains specifically to Avadel Pharmaceuticals. No additional parties or interests are mentioned regarding this disclosure. The filing indicates no dealings in cash-settled or stock-settled derivatives related to this position.

The only recorded transaction is the purchase of 350 shares at a price of USD 21.50 per share. No agreements or arrangements concerning options or derivatives are reported, and there are no Supplemental Form 8 attachments.